A Potential Drug For Liver Carcinoma
Main Category: Liver Disease / HepatitisAlso Included In: Biology / Biochemistry; Cancer / Oncology
Article Date: 25 May 2009 - 2:00 PDT
| Patient / Public: | ![]() |
4.33 (3 votes) |
| Healthcare Prof: | ![]() |
3.5 (2 votes) |
Looking for efficient anti-tumor drugs is a hot research area. Chrysin (5,7-dihydroxy flavone), a natural widely-distributed flavonoid, has been reported to have many different biological activities such as anti-oxidant, anti-virus, antidiabetogenic activity and clear anxiolytic effect. However, Chrysin is limited in its clinical application because of its modest absorption in the intestine and rapid in vivo glycosylation. To improve the biological activity of chrysin, a number of its derivatives have been prepared for biological testing. 5-allyl-7-gen-difluoromethylenechrysin (ADFMChR) is one of them.
A research team led by Dr. Jian-Guo Cao from China investigate the anti-tumor effect of ADFMChR in vitro. Their study was published on May 14, 2009 in the World Journal of Gastroenterology.
In their study, HepG2 cells and L-02 cells were cultured and the inhibitory effect of ADFMChR on their proliferation was measured by MTT assay. The apoptosis of HepG2 cells was determined by flow cytometry using propidium iodide fluorescence staining. The influence of ADFMChR on the proxisome proliferator-activated receptor γ (PPARγ), NF-κB, Bcl-2 and Bax protein expression of HepG2 cells were analyzed by Western blotting.
They found that ADFMChR significantly inhibited the proliferation of HepG2 cells in a dose-dependent manner, with little effect on growth of L-02 cells. Western blotting analysis revealed that after 24 h of treatment with 3.0, 10.0, 30.0 μmol/L ADFMChR, PPARγ and Bax protein expression increased but Bcl-2 and NF-κB expression decreased in HepG2 cells; however, pre-incubation with 10.0 μmol/L GW9662, a blocker of PPARγ, could efficiently antagonize and weaken the regulatory effect of 3.0, 30.0 μmol/L ADFMChR on PPARγ and NF-κB protein expression in HepG2 cells.
This finding may provide a molecular basis for the clinically observed cancer-preventive effects of ADFMChR and new clues for research about pharmaceutical prevention and cure of human liver carcinoma.
Reference: Tan XW, Xia H, Xu JH, Cao JG. Induction of apoptosis in human liver carcinoma HepG2 cell line by 5-allyl-7-gendifluoromethylenechrysin. World J Gastroenterol 2009; 15(18): 2234-2239 http://www.wjgnet.com/1007-9327/15/2234.asp
Correspondence to: Dr. Jian-Guo Cao, Laboratory of Medicine Engineering, Medical College, Hunan Normal University, Changsha 410006, Hunan Province, China.
Source:
Lai-Fu Li
World Journal of Gastroenterology
Visit our liver disease / hepatitis section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/151241.php>
APA
http://www.medicalnewstoday.com/releases/151241.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




